These data indicate that the majority of neuronal tau inclusion inhibitors act by alternative mechanisms, although compounds that do lower neuronal tau levels could still be interesting candidates for further study, as reducing neuronal tau expression through the use of ASOs has been suggested as a therapeutic strategy for AD and other tauopathies (44). Here, MAPT is linked to Alzheimer disease.